Lacosamid Ratiopharm (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This action reduces the ability of hyper‑excitable neurons to fire repeatedly, stabilizing the membrane and decreasing the spread of epileptic discharges, which helps to control seizures.

The specific dose of Lacosamid Ratiopharm is determined by the prescribing clinician based on the patient’s age, weight, renal and hepatic function, and response to therapy. Dosage adjustments are individualized, and patients should follow the prescriber’s instructions without self‑adjusting the dose.

Safety data for lacosamide in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To request Lacosamid Ratiopharm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Lacosamide’s mechanism—enhancing slow sodium‑channel inactivation—differs from many older agents that block fast inactivation (e.g., carbamazepine). This distinct profile can provide additive seizure control when combined with other antiepileptics, and it may have a lower risk of certain drug‑interaction effects compared with broader‑spectrum sodium‑channel blockers.

Lacosamid Ratiopharm tablets should be stored at ambient temperature, below 25 °C, in their original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

The medication is taken orally, usually with water. It can be administered with or without food, but patients should follow the prescriber’s guidance regarding timing relative to meals. Swallow the tablet whole; do not crush or chew unless specifically instructed by a healthcare professional.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, and the emergence of suicidal thoughts or behaviors. Patients should be monitored for these signs, and any concerning symptoms should prompt immediate medical evaluation.

Lacosamid Ratiopharm is contraindicated in patients with known hypersensitivity to lacosamide or any tablet excipients. Caution is advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or those taking other strong sodium‑channel blockers without appropriate monitoring.